Obesity Management Market Scenario and Elaborates Outlook to 2025
Author : Tom Williamson | Published On : 24 May 2021
The global obesity management market is poised to inflate to a valuation of USD 9.34 billion by 2025. It can exhibit a CAGR of 8.4% over the forecast period.
The lifestyle of convenience, consumption of snacks, large number of obese individuals, and availability of obesity treatment methods are major drivers of the market. According to a study in 2016, out of 2 billion overweight individuals, close to 650 million were found to be obese. The risk of being diagnosed with cardiovascular disease and diabetes due to obesity can provide plenty of growth opportunities to the global obesity management market.
Awareness of obesity management, presence of various healthy diets, option of bariatric surgery, and prevalence of lifestyle diseases can drive the market growth over the forecast period. Public health intervention campaigns endorsed by governments are likely to facilitate in market growth. Furthermore, the presence of nutrition experts and establishment of fitness centers can boost the global obesity management market.
The COVID-19 pandemic has created a massive opportunity for the market owing to people adhering to sedentary lifestyle and ordering in foods. Obesity management can reduce the susceptibility ratio of patients attaining the virus and further the market growth.
The global market for obesity management, by type, is divided into medication and surgery. Moreover, the medication segment is further classified into liraglutide, orlistat, lorcaserin, bupropion and naltrexone, and phentermine and topiramate. Furthermore, the surgery is sub-segmented into laparoscopic adjustable gastric band, gastric sleeve, and gastric bypass.
F. Hoffmann-La Roche Ltd, AstraZeneca, Merck Sharp & Dohme Corp., Apollo Endosurgery, GlaxoSmithKline plc., Herbalife Ltd., Pfizer Inc., and Ethicon, Inc. are notable players of the global obesity management market.